Anesiva Zingo gets fast-acting approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Aug. 16 approval of the fast-acting topical local analgesic comes five weeks ahead of the NDA's Sept. 24 user fee goal. The needle-free Zingo system delivers 0.5 mg lidocaine powder into the epidermis of the skin, providing local analgesia one to three minutes after administration. Commonly used local anesthetics take 20 minutes or longer to act, Anesiva notes. Zingo is approved to reduce pain associated with venous access procedures, such as IV insertions or blood draws, in children ages 3 to 18. The company plans to file an sNDA broadening the label to include adults by the end of the year...
You may also be interested in...
'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: